Akero Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Akero Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||||
| current assets: | |||||||||||||||||||||||||
| cash and cash equivalents | 220,449,000 | 185,922,000 | 340,238,000 | 316,065,000 | 310,355,000 | 623,854,000 | 234,207,000 | 269,546,000 | 444,156,000 | 257,884,000 | 249,773,000 | 374,003,000 | 177,727,000 | 150,489,000 | 150,483,000 | 164,935,000 | 157,538,000 | 187,960,000 | 187,242,000 | 192,679,000 | 63,247,000 | 47,245,000 | 64,788,000 | 147,835,000 | 162,654,000 |
| short-term marketable securities | 521,866,000 | 500,371,000 | 402,840,000 | 401,182,000 | 449,839,000 | 279,811,000 | 315,803,000 | 285,186,000 | 195,288,000 | 85,338,000 | 101,676,000 | 2,998,000 | 14,887,000 | 37,775,000 | 50,146,000 | 78,040,000 | 71,612,000 | ||||||||
| prepaid expenses and other current assets | 22,285,000 | 26,858,000 | 27,302,000 | 29,641,000 | 15,816,000 | 7,615,000 | 9,952,000 | 21,247,000 | 3,759,000 | 4,267,000 | 3,724,000 | 3,943,000 | 3,422,000 | 2,558,000 | 5,324,000 | 6,726,000 | 6,194,000 | 5,792,000 | 2,958,000 | 6,163,000 | 10,360,000 | 933,000 | 1,649,000 | 2,238,000 | 454,000 |
| total current assets | 764,600,000 | 713,151,000 | 770,380,000 | 746,888,000 | 776,010,000 | 911,280,000 | 559,962,000 | 575,979,000 | 643,203,000 | 347,489,000 | 355,173,000 | 377,946,000 | 184,147,000 | 167,934,000 | 193,582,000 | 221,807,000 | 236,222,000 | 255,776,000 | 271,345,000 | 298,033,000 | 113,193,000 | 126,218,000 | 138,049,000 | 150,073,000 | 163,108,000 |
| long-term marketable securities | 343,931,000 | 442,003,000 | 54,751,000 | 69,824,000 | 88,133,000 | 19,283,000 | 58,264,000 | 19,451,000 | |||||||||||||||||
| right of use asset | 621,000 | 689,000 | 755,000 | 820,000 | 884,000 | 946,000 | 1,008,000 | 1,068,000 | 1,127,000 | 1,185,000 | 1,242,000 | 1,297,000 | 1,352,000 | 1,406,000 | 1,459,000 | 226,000 | |||||||||
| total assets | 1,109,152,000 | 1,155,843,000 | 825,886,000 | 817,547,000 | 865,043,000 | 912,243,000 | 580,271,000 | 635,331,000 | 663,806,000 | 348,818,000 | 356,570,000 | 379,408,000 | 185,675,000 | 169,887,000 | 195,548,000 | 223,533,000 | 238,009,000 | 257,623,000 | 273,339,000 | 300,036,000 | 114,058,000 | 126,621,000 | 138,118,000 | 150,143,000 | 163,168,000 |
| liabilities and stockholders' equity | |||||||||||||||||||||||||
| current liabilities: | |||||||||||||||||||||||||
| accounts payable | 13,249,000 | 10,831,000 | 9,027,000 | 25,223,000 | 14,568,000 | 13,783,000 | 7,038,000 | 11,454,000 | 10,121,000 | 7,080,000 | 7,968,000 | 6,010,000 | 6,877,000 | 4,450,000 | 6,706,000 | 6,784,000 | 2,307,000 | 4,605,000 | 3,428,000 | 4,636,000 | 2,536,000 | 1,535,000 | 947,000 | 93,000 | 3,248,000 |
| accrued expenses and other current liabilities | 33,651,000 | 24,944,000 | 30,727,000 | 18,068,000 | 16,606,000 | 16,476,000 | 12,090,000 | 14,917,000 | 11,481,000 | 9,598,000 | 11,115,000 | 19,233,000 | 19,820,000 | 17,647,000 | 18,422,000 | 16,756,000 | 14,152,000 | 5,531,000 | 9,683,000 | 7,378,000 | 7,857,000 | 6,751,000 | 8,422,000 | 6,632,000 | 1,492,000 |
| loan payable, current | 13,501,000 | 6,664,000 | 2,076,000 | ||||||||||||||||||||||
| total current liabilities | 60,401,000 | 42,439,000 | 39,754,000 | 43,291,000 | 31,174,000 | 30,259,000 | 19,128,000 | 28,447,000 | 21,602,000 | 16,678,000 | 19,083,000 | 25,243,000 | 26,697,000 | 22,097,000 | 25,128,000 | 23,540,000 | 16,459,000 | 10,136,000 | 13,111,000 | 12,014,000 | 10,393,000 | 8,286,000 | 9,369,000 | 6,725,000 | 4,740,000 |
| loan payable, noncurrent | 22,160,000 | 28,811,000 | 35,297,000 | 35,123,000 | 34,959,000 | 34,803,000 | 24,964,000 | 22,768,000 | 24,728,000 | 24,616,000 | 9,541,000 | 9,447,000 | 9,366,000 | ||||||||||||
| warrant liability | 400,000 | 296,000 | 194,000 | 203,000 | 164,000 | 178,000 | 54,000 | 93,000 | 85,000 | 162,000 | 305,000 | 70,000 | 41,000 | ||||||||||||
| operating lease liability, noncurrent | 372,000 | 451,000 | 529,000 | 605,000 | 679,000 | 750,000 | 819,000 | 888,000 | 954,000 | 1,017,000 | 1,079,000 | 1,140,000 | 1,199,000 | 1,255,000 | 1,311,000 | 1,365,000 | |||||||||
| total liabilities | 83,333,000 | 71,997,000 | 75,774,000 | 79,222,000 | 66,976,000 | 65,990,000 | 44,965,000 | 52,196,000 | 47,369,000 | 42,473,000 | 30,008,000 | 35,900,000 | 37,303,000 | 23,352,000 | 26,439,000 | 24,905,000 | 8,298,000 | 9,392,000 | 6,759,000 | 4,779,000 | |||||
| commitments and contingencies | |||||||||||||||||||||||||
| stockholders’ equity: | |||||||||||||||||||||||||
| common stock | 8,000 | 8,000 | 7,000 | 7,000 | 7,000 | 7,000 | 6,000 | 6,000 | 6,000 | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 |
| additional paid-in capital | 1,992,209,000 | 1,979,634,000 | 1,575,313,000 | 1,492,347,000 | 1,481,748,000 | 1,473,765,000 | 1,109,126,000 | 1,102,545,000 | 1,095,933,000 | 754,487,000 | 748,857,000 | 742,781,000 | 512,107,000 | 482,894,000 | 479,436,000 | 476,521,000 | 473,688,000 | 470,635,000 | 468,238,000 | 466,254,000 | 261,983,000 | 260,481,000 | 259,049,000 | 258,090,000 | 257,541,000 |
| accumulated other comprehensive income | 988,000 | 1,085,000 | 948,000 | 2,103,000 | -261,000 | -79,000 | 270,000 | -506,000 | -251,000 | 21,000 | 37,000 | ||||||||||||||
| accumulated deficit | -967,386,000 | -896,881,000 | -826,156,000 | -756,132,000 | -683,427,000 | -627,440,000 | -574,096,000 | -518,910,000 | -479,251,000 | -448,168,000 | -422,337,000 | -399,278,000 | -363,736,000 | -336,333,000 | -310,304,000 | -277,880,000 | -253,550,000 | -224,617,000 | -209,527,000 | -179,816,000 | -158,413,000 | -142,206,000 | -130,320,000 | -114,709,000 | |
| total stockholders’ equity | 1,025,819,000 | 1,083,846,000 | 750,112,000 | 738,325,000 | 798,067,000 | 846,253,000 | 535,306,000 | 583,135,000 | 616,437,000 | 306,345,000 | 326,562,000 | 343,508,000 | 148,372,000 | 146,535,000 | 169,109,000 | 198,628,000 | 220,133,000 | 246,020,000 | 258,712,000 | 286,458,000 | 103,663,000 | 118,323,000 | 128,726,000 | 143,384,000 | 158,389,000 |
| total liabilities and stockholders’ equity | 1,109,152,000 | 1,155,843,000 | 825,886,000 | 817,547,000 | 865,043,000 | 912,243,000 | 580,271,000 | 635,331,000 | 663,806,000 | 348,818,000 | 356,570,000 | 379,408,000 | 185,675,000 | 169,887,000 | 195,548,000 | 223,533,000 | 238,009,000 | 257,623,000 | 273,339,000 | 300,036,000 | 114,058,000 | 126,621,000 | |||
| liabilities and stockholders’ equity | |||||||||||||||||||||||||
| property and equipment | 15,000 | 16,000 | 17,000 | 18,000 | 20,000 | 25,000 | 36,000 | 47,000 | 57,000 | 68,000 | 79,000 | 90,000 | 101,000 | ||||||||||||
| other assets, noncurrent | 108,000 | 108,000 | 108,000 | 108,000 | 468,000 | 417,000 | 114,000 | ||||||||||||||||||
| accumulated other comprehensive loss | -3,000 | -30,000 | -27,000 | -17,000 | |||||||||||||||||||||
| operating lease right-of-use asset | 1,511,000 | ||||||||||||||||||||||||
| other liabilities, noncurrent | |||||||||||||||||||||||||
| accumulated other comprehensive gain | 45,000 | ||||||||||||||||||||||||
| other assets | 177,000 | 69,000 | 10,000 | ||||||||||||||||||||||
| other liabilities | 12,000 | 23,000 | 34,000 | 39,000 | |||||||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ equity | |||||||||||||||||||||||||
| redeemable convertible preferred stock | |||||||||||||||||||||||||
| stockholders’ equity | |||||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ equity | 138,118,000 | 150,143,000 | 163,168,000 | ||||||||||||||||||||||
| restricted cash | 60,000 | 60,000 |
We provide you with 20 years of balance sheets for Akero Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Akero Therapeutics. Explore the full financial landscape of Akero Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Akero Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.